Jinran Zhan

Dr. Jinran Zhan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Pharmaceutical Statistics
Verified
Journal Article
Open access
JZJinran Zhan
Jinran Zhan
CKCornelia Ursula Kunz
Cornelia Ursula Kunz
NSNigel Stallard
Nigel Stallard
Two significant pivotal trials are usually required for a new drug approval by a regulatory agency. This standard requirement is known as the two‐trial paradigm. However, several authors have questioned why we need exactly two pivotal trials, what statistical error the regulators are trying to protect against, and potential alternative approaches. Therefore, it is important to investigate these questions to better understand the regulatory decision‐making in the assessment of drugs' effectiveness. It is common that two identically designed trials are run solely to adhere to the two‐trial rule. Previous work showed that combining the data from the two trials into a single trial (one‐trial paradigm) would increase the power while ensuring the same level of type I error protection as the two‐trial paradigm. However, this is true only under a specific scenario and there is little investigation on the type I error protection over the whole null region. In this article, we compare the two paradigms by considering scenarios in which the two trials are conducted in identical or different populations as well as with equal or unequal size. With identical populations, the results show that a single trial provides better type I error protection and higher power. Conversely, with different populations, although the one‐trial rule is more powerful in some cases, it does not always protect against the type I error. Hence, there is the need for appropriate flexibility around the two‐trial paradigm and the appropriate approach should be chosen based on the questions we are interested in.

10 November 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
AWAllen Wei-Jiat Wong
Allen Wei-Jiat Wong
NSNadia Hui-Shan Sim
Nadia Hui-Shan Sim
JZJinran Zhan
Jinran Zhan
JHJung-Ju Huang
Jung-Ju Huang

21 November 2025 in Journal of Endodontics
Verified
Journal Article
Closed access
PCPei Yuan Chan
Pei Yuan Chan
RSRachel Fangying Seet
Rachel Fangying Seet
Seyed Ehsan SaffariSeyed Ehsan Saffari
Seyed Ehsan Saffari
JZJinran Zhan
Jinran Zhan
NCNah Nah Chen
Nah Nah Chen

8 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JZJinran Zhan
Jinran Zhan
Seyed Ehsan SaffariSeyed Ehsan Saffari
Seyed Ehsan Saffari
Marcus Eng Hock OngMarcus Eng Hock Ong
Marcus Eng Hock Ong
FSFahad Javaid Siddiqui
Fahad Javaid Siddiqui
Background/Objectives: Clinical observational studies often encounter missing data, which complicates association evaluation with reduced bias while accounting for confounders. This is particularly challenging in multi-national registries such as those for out-of-hospital cardiac arrest (OHCA), a time-sensitive medical emergency with low survival rates. While various methods for handling missing data exist, observational studies frequently rely on complete-case analysis, limiting representativeness and potentially introducing bias. Our objective was to evaluate the impact of various single imputation methods on association analysis with OHCA registries. Methods: Using a complete dataset (N = 13,274) from the Pan-Asian Resuscitation Outcomes Study (PAROS) registry (1 January 2016–31 December 2020) as reference, we intentionally introduced missing values into selected variables via a Missing At Random (MAR) mechanism. We then compared statistical and machine learning (ML) single imputation methods to assess the association between bystander cardiopulmonary resuscitation (BCPR) and the issuance of a mobile app alert, adjusting for confounders. The impacts of complete-case analysis (CCA) and single imputation methods on conclusions in OHCA research were evaluated. Results: CCA was suboptimal for handling MAR data, resulting in more biased estimates and wider confidence intervals compared to single imputation methods. The missingness-indicator (MxI) method offered a trade-off between bias and ease of implementation. The K-Nearest Neighbours (KNN) method outperformed other imputation approaches, whereas missForest introduced bias under certain conditions. Conclusions: KNN and MxI are easy to use and better alternatives to CCA for reducing bias in observational studies. This study highlights the importance of selecting appropriate imputation methods to ensure reliable conclusions in OHCA research and has broader implications for other registries facing similar missing data challenges.

6 April 2026 in Journal of Clinical Periodontology
Verified
Journal Article
Open access
JTJohn Tay
John Tay
ENEthan Ng
Ethan Ng
DSDawn Shu Fen Siow
Dawn Shu Fen Siow
JZJinran Zhan
Jinran Zhan
Seyed Ehsan SaffariSeyed Ehsan Saffari
Seyed Ehsan Saffari
PPPhilip Preshaw
Philip Preshaw
Aim: To investigate whether the number of residual probing pocket depths (PPDs) ≥ 5 mm predicts periodontitis progression in non‐smoking patients undergoing supportive periodontal care (SPC). Materials and Methods: This retrospective study included 121 patients (3028 teeth), with Stage III/IV, Grade B/C periodontitis, who completed active periodontal therapy and were enrolled in SPC. Multivariable logistic regression with inverse probability censoring weighting assessed the association between the number of residual sites with PPD ≥ 5 mm at the start of SPC and disease progression at 1‐year and 5‐year intervals. Receiver operating characteristic (ROC) curve analysis was used to identify optimal thresholds for predicting progression. Results: Each additional site with PPD ≥ 5 mm at the start of SPC was associated with higher odds of disease progression (≥ 2 mm PPD increase at any site) after 1 year (adjusted OR: 1.15; 95% CI: 1.05–1.29). For periodontal tooth loss, each additional PPD ≥ 5 mm site increased the odds by 11% over 5 years. ROC analysis suggested that ≥ 6 residual sites provided the best discrimination for predicting 1‐year PD progression (AUC: 0.73). Conclusion: Six or more residual PPDs ≥ 5 mm at SPC were associated with short‐term disease progression, although the performance was modest.

28 July 2026 in Neurology
Verified
Journal Article
Closed access
STSimon Kang Seng Ting
Simon Kang Seng Ting
Seyed Ehsan SaffariSeyed Ehsan Saffari
Seyed Ehsan Saffari
JZJinran Zhan
Jinran Zhan
TGTushar Divikar Gosavi
Tushar Divikar Gosavi
SHShahul Hameed
Shahul Hameed
ANAdeline S.L. Ng
Adeline S.L. Ng
Seizures are a recognized comorbidity in dementia, with varying prevalence across Alzheimer disease (AD) and dementia with Lewy bodies (DLBs). Although previous studies have demonstrated an increased seizure risk in AD, the neuropathologic substrates underlying seizure susceptibility-particularly across dementia subtypes-remain incompletely understood. We aimed to identify distinct clinicopathologic correlates of clinically active seizures in AD and DLB using a large autopsy-confirmed cohort. We conducted a retrospective cohort study using data from the National Alzheimer's Coordinating Center (2005-December 2022). Autopsy-confirmed AD and DLB cases were included. Individuals with a history of stroke or traumatic brain injury were excluded. The primary outcome was clinically active seizures, defined as seizures occurring within 3 years before or after the diagnosis of dementia. Neuropathologic exposures included Braak stage, cerebral amyloid angiopathy (CAA), frontotemporal lobar degeneration, and vascular pathologies. Multivariable logistic regression models were used to examine associations between pathologic features and seizure occurrence, adjusting for relevant demographic covariates. A total of 3,498 participants were included, comprising 3,040 with AD (mean age, 73.4 years; 48.5% female) and 458 with DLB (mean age, 75.1 years; 31.4% female). Active seizures were identified in 174 participants with AD (5.7%) and 13 with DLB (2.8%). In AD, Braak stage VI (vs V) was associated with higher odds of active seizures (adjusted odds ratio [OR], 1.81; 95% CI 1.20-2.82; p = 0.007), as was moderate to severe CAA (adjusted OR, 1.38; 95% CI 1.01-1.90; p = 0.045). In DLB, AD-related pathologic features were not associated with seizures. By contrast, vascular pathology was significantly associated with seizure occurrence, including microinfarcts (adjusted OR, 5.11; 95% CI 1.64-16.4; p = 0.005) and infarcts (adjusted OR, 4.11; 95% CI 1.27-12.9; p = 0.015). In this autopsy-confirmed cohort, seizure susceptibility was associated with advanced tau pathology and CAA in AD. In DLB, exploratory analyses suggested a possible association between vascular pathology and seizures; however, these findings should be interpreted cautiously. Overall, the results support potentially distinct pathologic contributions to seizure susceptibility across dementia subtypes. Limitations include the use of advanced-stage pathologic samples, which may limit generalizability to earlier disease stages.